These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 34790170)

  • 1. Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease.
    Shaffner J; Chen B; Malhotra DK; Dworkin LD; Gong R
    Front Endocrinol (Lausanne); 2021; 12():749010. PubMed ID: 34790170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?
    Leehey DJ
    Kidney360; 2020 Apr; 1(4):292-299. PubMed ID: 35372914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
    Mima A
    J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransporter-2 inhibitors for diabetic kidney disease: Targeting Warburg effects in proximal tubular cells.
    Morita M; Kanasaki K
    Diabetes Metab; 2020 Oct; 46(5):353-361. PubMed ID: 32891754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
    Liu H; Sridhar VS; Perkins BA; Rosenstock J; Cherney DZI
    Curr Diab Rep; 2022 Jul; 22(7):317-332. PubMed ID: 35633439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New progress in drugs treatment of diabetic kidney disease.
    Wang J; Xiang H; Lu Y; Wu T; Ji G
    Biomed Pharmacother; 2021 Sep; 141():111918. PubMed ID: 34328095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review.
    Song J; Li X; Ni J
    Kidney Blood Press Res; 2023; 48(1):599-610. PubMed ID: 37717569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease.
    Stanton RC
    Semin Nephrol; 2021 Mar; 41(2):85-95. PubMed ID: 34140099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease.
    Gan T; Song Y; Guo F; Qin G
    Mol Biol Rep; 2022 Nov; 49(11):10915-10924. PubMed ID: 36002651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
    Barrera-Chimal J; Jaisser F
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms.
    Kashihara N; Kidokoro K; Kanda E
    Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):112-118. PubMed ID: 31725011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal intrinsic cells remodeling in diabetic kidney disease and the regulatory effects of SGLT2 Inhibitors.
    Guo W; Li H; Li Y; Kong W
    Biomed Pharmacother; 2023 Sep; 165():115025. PubMed ID: 37385209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease.
    Alicic RZ; Neumiller JJ; Johnson EJ; Dieter B; Tuttle KR
    Diabetes; 2019 Feb; 68(2):248-257. PubMed ID: 30665953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics.
    Kim NH; Kim NH
    Diabetes Metab J; 2022 Jul; 46(4):543-551. PubMed ID: 35929172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data.
    Mittal N; Sehray V; Mittal R; Singh S
    Eur J Pharmacol; 2021 Sep; 907():174320. PubMed ID: 34246651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.
    Fioretto P; Avogaro A
    Expert Opin Pharmacother; 2017 Apr; 18(5):517-527. PubMed ID: 28277831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.